Mika Derynck

Direktor/Vorstandsmitglied bei ENLIVEN THERAPEUTICS, INC.

Vermögen: - $ am 31.05.2024

61 Jahre

Health Technology

Consumer Services

Aktive Positionen von Mika Derynck

Unternehmen	Position	Beginn	Ende
ENLIVEN THERAPEUTICS, INC.	Direktor/Vorstandsmitglied	23.02.2023	-
ENLIVEN THERAPEUTICS, INC.	Independent Dir/Board Member	23.02.2023	-
Enliven Therapeutics, Inc. /US/ Enliven Therapeutics, Inc. /US/ BiotechnologyHealth Technology EnLiven Therapeutics, Inc. engages in the discovery and development of small molecule treatments for cancer. The company was founded by Samuel S. Kintz and is headquartered in San Francisco, CA.	Direktor/Vorstandsmitglied	19.01.2022	-
Amunix Pharmaceuticals, Inc. Amunix Pharmaceuticals, Inc. BiotechnologyHealth Technology Amunix Pharmaceuticals, Inc. manufactures and fabricates drugs. The firm’s pipeline products are based on proprietary XTEN half-life extension, Antibody-XTEN-Drug Conjugate, ProTIA pro-drug and bispecific T-cell engager platform technologies. The company was founded by Willem P.C. Stemmer and Volker Schellenberger in 2006 and is headquartered in Mountain View, CA.	Technik-/Wissenschafts-/F&E-Leiter	-	-

Boston University	Undergraduate Degree
Boston University School of Medicine	Doctorate Degree

International

Vereinigte Staaten	5
Israel	2

Operativ

Director/Board Member	2
Chief Tech/Sci/R&D Officer	1
Independent Dir/Board Member	1

Sektoral

Health Technology	4
Consumer Services	3

Besetzte Positionen

Aktive

Inaktive

Börsennotierte Unternehmen

Private Unternehmen

Börsennotierte Unternehmen	1
ENLIVEN THERAPEUTICS, INC.	Health Technology

Private Unternehmen	2
Enliven Therapeutics, Inc. /US/ Enliven Therapeutics, Inc. /US/ BiotechnologyHealth Technology EnLiven Therapeutics, Inc. engages in the discovery and development of small molecule treatments for cancer. The company was founded by Samuel S. Kintz and is headquartered in San Francisco, CA.	Health Technology
Amunix Pharmaceuticals, Inc. Amunix Pharmaceuticals, Inc. BiotechnologyHealth Technology Amunix Pharmaceuticals, Inc. manufactures and fabricates drugs. The firm’s pipeline products are based on proprietary XTEN half-life extension, Antibody-XTEN-Drug Conjugate, ProTIA pro-drug and bispecific T-cell engager platform technologies. The company was founded by Willem P.C. Stemmer and Volker Schellenberger in 2006 and is headquartered in Mountain View, CA.	Health Technology

Private Unternehmen

Health Technology